Syntax Bio published research in Science Advances describing a CRISPR‑based ‘Cellgorithm’ platform that programs gene activity to accelerate and standardize human stem‑cell differentiation. The approach aims to replace slow, variable manual workflows and shorten timelines for generating differentiated cell types from months to weeks, potentially speeding preclinical work and cell‑therapy manufacturing. Authors position the method as a programmable alternative to conventional differentiation protocols; the company flagged implications for scaling cell‑therapy discovery and manufacturing pipelines.